OAM
KERX

Oxford Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Oxford Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-451,190
Closed -$6.95M – 801
2014
Q2 		$6.95M Buy
+451,190
New +$6.4M 0.23% 122

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Oxford Asset Management's KERX Position: Q3 2014 in Review

Oxford Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2014, closing a stake of 451,190 shares — an estimated $6.95M sold.

Oxford Asset Management first reported a position in KERX in Q2 2014 and held it in 1 quarter. The position peaked at $6.95M in Q2 2014. 140 funds tracked by Wall St. Rank hold KERX as of Q3 2014.

  • Oxford Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2014 after selling out during the quarter.
  • Oxford Asset Management sold 451,190 Keryx Biopharmaceuticals Inc shares in Q3 2014, an estimated $6.95M.
  • Oxford Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2014 and held it in 1 quarter.
  • Oxford Asset Management's Keryx Biopharmaceuticals Inc position peaked at $6.95M in Q2 2014.
  • 140 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2014.

Based on Oxford Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.